Aquestive Therapeutics, Inc. (AQST)

NGM – Real vaqt narxi. Valyuta: USD

4.29

-0.12 (-2.76%)

Bozor ochiq: Aug 12, 2026, 1:52 PM EDT

4.38

-0.03 (-0.68%)

Oldingi bozordan keyin: Aug 11, 2026, 7:57 PM EDT

12.08.2026

Aquestive Therapeutics Q2 Earnings Call Highlights

Aquestive Therapeutics NASDAQ: AQST said it plans to resubmit its new drug application for Anaphylm, its epinephrine sublingual film candidate for type 1 allergic reactions including anaphylaxis, before the end of the third quarter after completing studies requested by the U.S. Food and Drug Administration.

11.08.2026

Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates

Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.14 per share a year ago.

11.08.2026

Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

WARREN, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced financial results for the second quarter ended June 30, 2026, and provided a strategic business update.

10.08.2026

Aquestive Prepares FDA Resubmission for Severe Allergy Treatment Following Successful Study

Aquestive Therapeutics Inc. (NASDAQ:AQST) announced positive findings from human factors and pharmacokinetic validation studies for its Anaphylm (dibutepinephrine) sublingual film.

10.08.2026

Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film

Human factors and clinical study results support planned resubmission of Anaphylm™ NDA in the third quarter of 2026 Self-administration pharmacokinetic (PK) results were comparable to clinician-administered PK results Revised packaging design reduced median time to open pouch from 17 seconds in the previous human factors study to 3 seconds Revised instructions for use reduced incorrect film placement from previous human factors validation study by over 80% Top-of-tongue PK arm showed clinically meaningful pharmacodynamic (PD) results WARREN, N.J., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced results from its human factors (HF) validation study and pharmacokinetic (PK) study for Anaphylm™ (dibutepinephrine) sublingual film, conducted in support of the Company's planned resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the treatment of Type 1 allergic reactions, including anaphylaxis.

Videolar

No Data

There is no data to display

Press-relizlar

11.08.2026

Aquestive Therapeutics, Inc. (AQST)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Aquestive Therapeutics, Inc. (AQST)

Aquestive Therapeutics Q2 Earnings Call Highlights

Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates

Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Aquestive Prepares FDA Resubmission for Severe Allergy Treatment Following Successful Study

Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film

Videolar

No Data

Press-relizlar

Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Aquestive Therapeutics Q2 Earnings Call Highlights

Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates

Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Aquestive Prepares FDA Resubmission for Severe Allergy Treatment Following Successful Study

Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film

Videolar

No Data

Press-relizlar

Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film

Search stocks

Aquestive Therapeutics, Inc. (AQST)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Aquestive Therapeutics, Inc. (AQST)

Aquestive Therapeutics Q2 Earnings Call Highlights

Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates

Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Aquestive Prepares FDA Resubmission for Severe Allergy Treatment Following Successful Study

Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film

Videolar

No Data

Press-relizlar

Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Aquestive Therapeutics Q2 Earnings Call Highlights

Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates

Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Aquestive Prepares FDA Resubmission for Severe Allergy Treatment Following Successful Study

Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film

Videolar

No Data

Press-relizlar

Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film